KR20220157392A - 알파-2-아드레날린성 수용체 효능제의 약제학적 조성물 및 시력 개선을 위한 이의 용도 - Google Patents
알파-2-아드레날린성 수용체 효능제의 약제학적 조성물 및 시력 개선을 위한 이의 용도 Download PDFInfo
- Publication number
- KR20220157392A KR20220157392A KR1020227032439A KR20227032439A KR20220157392A KR 20220157392 A KR20220157392 A KR 20220157392A KR 1020227032439 A KR1020227032439 A KR 1020227032439A KR 20227032439 A KR20227032439 A KR 20227032439A KR 20220157392 A KR20220157392 A KR 20220157392A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- improvement
- subject
- reduction
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979214P | 2020-02-20 | 2020-02-20 | |
| US62/979,214 | 2020-02-20 | ||
| PCT/US2021/018906 WO2021168349A1 (en) | 2020-02-20 | 2021-02-19 | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220157392A true KR20220157392A (ko) | 2022-11-29 |
Family
ID=74875311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227032439A Withdrawn KR20220157392A (ko) | 2020-02-20 | 2021-02-19 | 알파-2-아드레날린성 수용체 효능제의 약제학적 조성물 및 시력 개선을 위한 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210260041A1 (https=) |
| EP (1) | EP4106728A1 (https=) |
| JP (1) | JP2023514732A (https=) |
| KR (1) | KR20220157392A (https=) |
| CN (1) | CN115443125A (https=) |
| AU (1) | AU2021224232A1 (https=) |
| BR (1) | BR112022016730A2 (https=) |
| CA (1) | CA3168767A1 (https=) |
| IL (1) | IL295782A (https=) |
| MX (1) | MX2022010317A (https=) |
| TW (1) | TW202139998A (https=) |
| WO (1) | WO2021168349A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3209420A1 (en) | 2021-02-24 | 2022-09-01 | Peter Jarrett | Intracanalicular depot inserter device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| CN102821753A (zh) | 2010-01-22 | 2012-12-12 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| WO2014143754A2 (en) | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| EP2978406A1 (en) | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| AU2014248460B2 (en) | 2013-04-01 | 2019-04-11 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| TW202021584A (zh) * | 2018-08-21 | 2020-06-16 | 美商歐樂根公司 | α2 腎上腺素受體促效劑用於改善視力之用途 |
-
2021
- 2021-02-19 CN CN202180027733.2A patent/CN115443125A/zh active Pending
- 2021-02-19 KR KR1020227032439A patent/KR20220157392A/ko not_active Withdrawn
- 2021-02-19 IL IL295782A patent/IL295782A/en unknown
- 2021-02-19 WO PCT/US2021/018906 patent/WO2021168349A1/en not_active Ceased
- 2021-02-19 TW TW110105859A patent/TW202139998A/zh unknown
- 2021-02-19 EP EP21712314.0A patent/EP4106728A1/en not_active Withdrawn
- 2021-02-19 AU AU2021224232A patent/AU2021224232A1/en not_active Abandoned
- 2021-02-19 US US17/180,532 patent/US20210260041A1/en not_active Abandoned
- 2021-02-19 MX MX2022010317A patent/MX2022010317A/es unknown
- 2021-02-19 BR BR112022016730A patent/BR112022016730A2/pt not_active Application Discontinuation
- 2021-02-19 CA CA3168767A patent/CA3168767A1/en active Pending
- 2021-02-19 JP JP2022550240A patent/JP2023514732A/ja active Pending
-
2024
- 2024-02-12 US US18/439,468 patent/US20240335425A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4106728A1 (en) | 2022-12-28 |
| MX2022010317A (es) | 2023-01-24 |
| AU2021224232A1 (en) | 2022-10-13 |
| CA3168767A1 (en) | 2021-08-26 |
| US20210260041A1 (en) | 2021-08-26 |
| BR112022016730A2 (pt) | 2022-11-08 |
| TW202139998A (zh) | 2021-11-01 |
| JP2023514732A (ja) | 2023-04-07 |
| US20240335425A1 (en) | 2024-10-10 |
| CN115443125A (zh) | 2022-12-06 |
| WO2021168349A1 (en) | 2021-08-26 |
| IL295782A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7470667B2 (ja) | 眼の状態の治療のためのピロカルピン塩酸塩の使用 | |
| KR102472774B1 (ko) | 안과용 약학 조성물 및 이와 관련된 용도 | |
| US20240358682A1 (en) | Use of alpha-2-adrenergic receptor agonists for improving vision | |
| US20240390330A1 (en) | Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes | |
| US20240335425A1 (en) | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision | |
| US11077053B2 (en) | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia | |
| HK40053072A (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| Bishop et al. | Ophthalmology cystinosis fórum afternoon sesión | |
| HK40034331A (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
| HK40034331B (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |